CMS Issues an FAQ on the IRA’s Changes to Part B Cost Sharing Provisions

- On July 13, 2023, the Centers for Medicare and Medicaid Services (CMS) issued a memo titled Frequently Asked Questions: Inflation Reduction Act Changes to Cost Sharing for Part B Drugs for Medicare Advantage and Section 1876 Cost Plans (FAQs).

- The purpose of the FAQs is to clarify the application of the beneficiary cost sharing protections under section 11101 and section 11407 of the Inflation Reduction Act (IRA) which were also addressed in the November 7, 2022, HPMS memorandum titled, “Inflation Reduction Act Changes to Cost Sharing for Medicare Part B Drugs for Contract Year 2023 Medicare Advantage and Section 1876 Cost Plans” (November 2022 IRA Memo).

- Among the topics covered by the FAQs are:
  - Refunds of excess cost sharing by Medicare Advantage (MA) Organizations (MAOs) or their delegated contract providers.
  - Reporting the Part B rebatable drug adjusted coinsurance at the point of sale (POS) or on the explanation of benefits (EOB).
  - Part B Insulin Cost Sharing Cap
  - Part B Rebatable Drug Coinsurance Adjustment Implementation
  - Medicare Plan Finder and Communication Materials

See the FAQs for additional details.

More on This Topic

- FAQs
- November 2022 IRA Memo

For questions, please reach out to Tyler Thorne.